ReviewCurrent diabetes reports2008
Effects of chronic hyperinsulinemia in insulin-resistant patients.
Review in Current diabetes reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Trial
- Insulin resistance in the 21st century: new takes on an old problem-2025 Diabetes, Diabetes Care, and Diabetologia Expert Forum.Diabetologia · 2026Review
- Light and Shadow of Na-Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Points for Improvement Based on Our Clinical Experience.International journal of endocrinology · 2024Article
- Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?World journal of diabetes · 2014 · on this mapReview
- A control engineering approach to understanding the TGF-β paradox in cancer.Journal of the Royal Society, Interface · 2012Article
- Mechanism of the mitogenic influence of hyperinsulinemia.Diabetology & metabolic syndrome · 2011Article
- The association between C-reactive protein levels and insulin therapy in obese vs nonobese veterans with type 2 diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2010Article
- Mitogenic action of insulin: friend, foe or 'frenemy'?Diabetologia · 2010Article
- Quantitative modeling and analysis of the transforming growth factor beta signaling pathway.Biophysical journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective insulin resistance influences pathogenesis and treatment of type 2 diabetes and metabolic syndrome. Downregulation of the antiatherogenic pathway and maintained activity of the proatherogenic and cancerogenic pathways lead to atherosclerosis and cancer. Exogenous insulin added to "compensatory" hyperinsulinemia might worsen the primary end points, resulting in potential increase in cardiovascular and cancer events in spite of improvement of surrogate metabolic end points. Conversely, metformin can improve primary and surrogate end points.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.